Hillevax Stock Today
| HLVX Stock | USD 1.86 0.04 2.20% |
Performance0 of 100
| Odds Of DistressOver 75
|
Hillevax is trading at 1.86 as of the 25th of November 2024; that is 2.20 percent increase since the beginning of the trading day. The stock's open price was 1.82. Hillevax has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Hillevax are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 6th of December 2022 and ending today, the 25th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 29th of April 2022 | Category Healthcare | Classification Health Care |
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company has 49.81 M outstanding shares of which 1.18 M shares are currently shorted by private and institutional investors with about 8.81 trading days to cover. More on Hillevax
Moving against Hillevax Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Hillevax Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsHillevax can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Hillevax's financial leverage. It provides some insight into what part of Hillevax's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Hillevax (HLVX) is traded on NASDAQ Exchange in USA. It is located in 321 Harrison Avenue, Boston, MA, United States, 02118 and employs 90 people. Hillevax is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 92.64 M. Hillevax conducts business under Biotechnology sector and is part of Health Care industry. The entity has 49.81 M outstanding shares of which 1.18 M shares are currently shorted by private and institutional investors with about 8.81 trading days to cover.
Hillevax currently holds about 292.06 M in cash with (86.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.81, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Hillevax Probability Of Bankruptcy
Ownership AllocationHillevax has a total of 49.81 Million outstanding shares. The majority of Hillevax outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Hillevax to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Hillevax. Please pay attention to any change in the institutional holdings of Hillevax as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Hillevax Ownership Details
Hillevax Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-09-30 | 627.7 K | |
| State Street Corp | 2024-06-30 | 595.4 K | |
| Qiming U.s. Ventures Management, Llc | 2024-09-30 | 558.9 K | |
| Millennium Management Llc | 2024-06-30 | 490 K | |
| Trium Capital Llp | 2024-09-30 | 453.3 K | |
| Deutsche Bank Ag | 2024-06-30 | 311.6 K | |
| Northern Trust Corp | 2024-09-30 | 242.7 K | |
| Catalys Pacific Llc | 2024-09-30 | 236.4 K | |
| Citadel Advisors Llc | 2024-09-30 | 175.5 K | |
| Tang Capital Management Llc | 2024-09-30 | 4.9 M | |
| Blackrock Inc | 2024-06-30 | 2.1 M |
Hillevax Historical Income Statement
Hillevax Stock Against Markets
Hillevax Corporate Management
| Anju Chatterji | VP Operations | Profile | |
| Kaia Agarwal | VP Affairs | Profile | |
| Astrid MD | Chief Officer | Profile | |
| Sean McLoughlin | Chief Officer | Profile | |
| Paul JD | Secretary Counsel | Profile | |
| Ozzie Berger | Senior Affairs | Profile |
Additional Tools for Hillevax Stock Analysis
When running Hillevax's price analysis, check to measure Hillevax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hillevax is operating at the current time. Most of Hillevax's value examination focuses on studying past and present price action to predict the probability of Hillevax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hillevax's price. Additionally, you may evaluate how the addition of Hillevax to your portfolios can decrease your overall portfolio volatility.